Indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer: 🔹 Initial therapy: In combination with an aromatase inhibitor (e.g., Letrozole) in postmenopausal women. 🔹 Subsequent therapy: In combination with Fulvestrant in women with disease progression following endocrine therapy.

Dosage and administration

Packaging: 125 mg capsules. ⚠️ ADMINISTRATION PROTOCOL (28-day cycle): Dose: One capsule (125 mg) taken orally once daily. Schedule: Take for 21 consecutive days, followed by a 7-day break (no treatment). With Food: Must be taken with food to ensure consistent absorption. Avoid: Do not consume grapefruit or grapefruit juice during treatment.

Hypersensitivity to Palbociclib. Pregnancy and breastfeeding (embryo-fetal toxicity). Severe hepatic or renal impairment (dose adjustment may be required).

The most common adverse reaction is hematologic toxicity: 🩸 Neutropenia: Low white blood cell count is very common. Regular Complete Blood Counts (CBC) are mandatory before starting each cycle. 🌀 General: Fatigue, nausea, anemia, alopecia (hair thinning). 🤒 Infections: Increased risk of upper respiratory tract infections.

Palboxen — Palbociclib 125 mg, 21 pcs, Everest

100% original product

Active ingredient

Palbociclib

Manufacturer

Everest

Dosage 125 mg

Dosage form Capsules

Capsules per pack 21

Palboxen (Palbociclib) Capsules

Name: Palboxen
Brand: Everest
SKU: PROD-135
Price: 21975 UAH
Availability: InStock

21975₴ ~~24611₴~~ -11%

Palboxen 125 mg (Palbociclib) is a targeted cancer therapy classified as a CDK4/6 inhibitor.

Manufacturer: Everest Pharmaceuticals. Each bottle contains 21 capsules, designed for precisely one dosing cycle. It works by interrupting the cell division cycle of cancer cells, effectively stopping the tumor from growing.

Clinical Application:

It is prescribed for women with specific types of breast cancer to delay disease progression. It is always used in combination with endocrine (hormonal) therapy.

Indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer:

🔹 Initial therapy: In combination with an aromatase inhibitor (e.g., Letrozole) in postmenopausal women.
🔹 Subsequent therapy: In combination with Fulvestrant in women with disease progression following endocrine therapy.

Packaging: 125 mg capsules.

⚠️ ADMINISTRATION PROTOCOL (28-day cycle):

Dose: One capsule (125 mg) taken orally once daily.
Schedule: Take for 21 consecutive days, followed by a 7-day break (no treatment).
With Food: Must be taken with food to ensure consistent absorption.
Avoid: Do not consume grapefruit or grapefruit juice during treatment.

Hypersensitivity to Palbociclib.
Pregnancy and breastfeeding (embryo-fetal toxicity).
Severe hepatic or renal impairment (dose adjustment may be required).

The most common adverse reaction is hematologic toxicity:

🩸 Neutropenia: Low white blood cell count is very common. Regular Complete Blood Counts (CBC) are mandatory before starting each cycle.
🌀 General: Fatigue, nausea, anemia, alopecia (hair thinning).
🤒 Infections: Increased risk of upper respiratory tract infections.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 09.04.2026